key: cord-0951262-jm1z8e1m authors: Theel, Elitza S. title: Performance Characteristics of High-Throughput Serologic Assays for SARS-CoV-2 with FDA Emergency Use Authorization: A Review date: 2021-11-03 journal: Clin Lab Med DOI: 10.1016/j.cll.2021.10.006 sha: 4145ad1557898fc7536ce767c6da6719250f5981 doc_id: 951262 cord_uid: jm1z8e1m This review provides a broad summary of the performance characteristics of high-throughput SARS-CoV-2 serologic assays with Food and Drug Administration Emergency Use Authorization, which are commonly found in central clinical laboratories. Additionally, this review discusses the current roles of serologic testing for SARS-CoV-2 and provides a perspective for the future. Throughout the coronavirus disease 2019 pandemic, the role of serologic 43 testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been debated 44 among clinicians and laboratorians. In contrast, among both public and government forums, 45 interest in this methodology has oscillated between 'none,' to headlines suggesting that such 46 testing may help to 'reopen economies' 1, 2 . In reality, the truth lies somewhere in between these 47 two dichotomies. Currently, the role of serologic testing for SARS-CoV-2 in the clinical realm 48 remains fairly limited, and of note, has not significantly changed since the start of the pandemic. 49 These potential uses, not solely limited to the clinical setting, include the following 3-5 : 50  Aid in the diagnosis of COVID-19 in patients with a negative SARS-CoV-2 molecular or 51 antigen detection assay, who present at least seven days after disease onset and with a 52 prior negative antibody test result, 53  Aid in the diagnosis of complications associated with COVID-19, including multisystem Therefore, the reported values are not interchangeable across platforms and significant variability 99 has been observed between methods 9,10 . Another key differential feature of serologic assays is the SARS-CoV-2 antigen they are 101 based on, which varies between epitopes of either the viral spike (S) glycoprotein or the 102 nucleocapsid (NC) protein (Table 1 ). The S glycoprotein decorates the surface of SARS-CoV-2 103 and mediates binding to and fusion with the human angiotensin-converting enzyme 2 (ACE2) for 104 cellular entry, and is also the primary target for neutralizing antibodies to the virus 11 . More 105 specifically, each monomer of the S trimer is composed of two subunits -S1 and S2. Within the 106 S1 subunit lies the receptor binding domain (RBD), which specifically interacts with the ACE2 107 receptor for binding. The majority of high-throughput serologic assays have been designed to 108 detect antibodies to recombinant versions of the RBD, followed by recombinant S or S1 antigens 109 (Table 1) . Less frequently, manufacturers have used recombinant SARS-CoV-2 NC as the target 110 J o u r n a l P r e -p r o o f antigen, which is also highly immunogenic, but is involved with viral RNA replication, 111 packaging and viral particle release 12 . Although there are some reports suggesting differential 112 sensitivity of serologic assays based on whether SARS-CoV-2 S or NC components are targeted, 113 knowing which antigen the serologic assay is based on is increasingly important from the 114 perspective of result interpretation in the setting of increasing SARS-CoV-2 vaccination rates. 115 Currently, all of the SARS-CoV-2 vaccines with FDA EUA are designed to induce a humoral 116 and cellular immune response to the S glycoprotein 13 . Therefore, while anti-S/RBD/S1/S2 based 117 serologic assays may result as positive in either vaccinated or naturally infected individuals, anti-118 NC assays will only be positive in those who have had a prior natural infection with SARS-CoV-119 2. The final key differential feature among high-throughput SARS-CoV-2 serologic assays 121 is the antibody type and the class or classes of antibodies detected (Table 1) . Currently, all but 122 one of the serologic assays with FDA EUA detecting binding antibodies to the virus, with a 123 single assay specifically detecting neutralizing antibodies (nAb; cPass GenScript USA Inc.). While binding antibodies will recognize different immunogenic viral epitopes, their binding may 125 either not impact infectivity, or they may recruit other components of the immune system to help 126 inactivate the virus (eg, via opsonization or complement fixation). In contrast, nAb recognize and 127 specifically bind to viral epitopes involved with cellular entry and replication, resulting in the 128 inhibition of viral infectivity, independent of other elements of the immune system. The presence 129 of nAb has typically been used as a correlate for protective immunity for a variety of infectious 130 diseases, and has been shown to increase alongside binding antibodies following both natural 131 infection with and vaccination against SARS-CoV-2 [14] [15] [16] [17] . detailed documents for verification of serologic assays with EUA during a pandemic, to which 146 the reader is referred 18, 19 . With the rapid development and deployment of SARS-CoV-2 serologic tests and 148 increasing unease regarding the accuracy associated with a number of these assays, the FDA put 149 forth an easily accessible summary of assay-specific performance characteristics, which were 150 used to base the decision for EUA authorization 20 . These data were provided by the assay 151 manufacturer as part of the EUA application process and/or from testing performed at the 152 National Cancer Institute, and are summarized in Table 1 . Overall, sensitivity and specificity 153 values for these assays were high, ranging from 90% to 100% and 97.5% to 100%, respectively. infections worldwide, including HKU1, OC43, 229E and NL63. Therefore, a primary concern 170 among both manufacturers and laboratorians considering implementing SARS-CoV-2 serologic 171 tests, was what level of specificity could such assays achieve given that over 65% of children 172 and over 90% of adults over the age of 50 years are seropositive for antibodies to at least one of 173 the commonly circulating CoVs 21,22 . At the amino acid level, the endemic CoVs share 28.4%-174 34.6%, 21%-31.2% and 33.1%-42.3% identity with the SARS-CoV-2 NC, S1 and S2 proteins, 175 respectively, indicating that antibody cross-reactivity is possible among these viruses 23, 24 . the Bio-Rad Platelia assay has been most frequently evaluated, with slightly lower overall 192 specificity reported, ranging from 95% to 100% using similar panels ( Table 2) 28,29 . 193 The majority of high-throughput SARS-CoV-2 serologic assays are based on 194 recombinant spike protein components, either S1 or RBD, or a combination. The reported 195 specificity range for CIA-based anti-S assays is similarly high as that observed for NC-based 196 methods, typically above 99% (Table 2) . Two frequently evaluated S-based assays for which 197 lower specificities have more been reported include the DiaSorin S1/S2 IgG CIA and the 87.7%, respectively 10 . While these data are based on a small cross-reactivity panel set (N= 81 204 samples), this study is among the few to attempt to identify the potential causes of cross-205 reactivity, although no consistent cause was determined for these two assays. Implementing highly specific SARS-CoV-2 serologic assays is essential in order to [34] [35] [36] [37] . While some of this discrepancy is likely due to variability in the assays themselves, it 229 is increasingly apparent that immune responses are also impacted by disease severity, 230 immunocompetence, age and sex, among other factors 38, 39 . (Table 2) . Interestingly, the one assay that did not reach at least 90% sensitivity among samples 28, 29, 43 . This is notably discordant 249 with the 96.8% -100% positive percent agreement indicated by the manufacturer and as 250 published on the FDA website for this assay 6 . In an effort to optimize the performance 251 characteristics of the assay, Therrien and colleagues proposed an alternative cut-off threshold for 252 the Beckman IgG CIA, which improved sensitivity to 100% without substantially impacting 253 specificity 29 . While further study of the Beckman IgG CIA is warranted, this underscores the 254 importance of independent clinical assessment of these assays in local hospitals and healthcare 255 systems prior to assay implementation. vaccination are associated with protection for at least 6 to 9 months, however, it is also evident 268 as discussed above, that antibody titers can be quite variable among individuals, in both their 269 levels and persistence 15, 16, 34, 45 . Once such a threshold is established and the availability of SARS- CoV-2 vaccines stabilizes, results from SARS-CoV-2 serologic tests may provide more value -271 for example, they may be used to identify individuals who may benefit from re-vaccination. Alongside the identification of a 'minimum' antibody threshold associated with 273 protective immunity, there will be a need to standardize SARS-CoV-2 serologic assays. The high-throughput SARS-CoV-2 serologic assays ( Table 2) . As this review has summarized, the 291 reported specificity for the majority of these assays is exceedingly high, above 98% among both 292 pre-pandemic and cross-reactivity panels. As with most other anti-viral serologic assays, 293 J o u r n a l P r e -p r o o f sensitivity is poor-to-low during the first week PSO for the majority of patients, increasing 294 dramatically among samples collected at least 14 days after disease onset. While most high-295 throughput assays approached 100% sensitivity at these later timepoints, some assays did not 296 (eg., Beckman IgG CIA, DiaSorin IgG CIA), further underscoring the importance of clinical 297 validation of assays prior to implementation ( Table 2 ). The role of serologic testing for SARS- CoV-2 in the future remains difficult to predict. The clinical utility of these assays will likely 299 remain limited given that most individuals will have been naturally infected or vaccinated. done for other VPDs prior to arriving on campus or starting a job in healthcare, may become a 305 key role for these assays. In this case, high-throughput, specific SARS-CoV-2 serologic tests, 306 primarily targeting detection of spike protein components, will be key to fill this need. Abbreviations: CMIA, chemiluminescent microparticle immunoassay; CIA, chemiluminescent immunoassay; NC, nucleocapsid; FDA, US Food and Drug Administration; S, spike glycoprotein; S1, spike glycoprotein subunit 1; S2, spike glycoprotein subunit 2; RBD, receptor binding domain; ELFA, enzyme linked fluorescence assay; ELISA, enzyme-linked immunosorbent assay; nAb, neutralizing antibody; FMIA, fluorescent microbead immunoassay; a Laboratories may alternatively validate these on fully automated ELISA processors b Data from FDA EUA Authorized Serology Test Performance: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance Antibody testing can help open the economy and get us working again Could a simple blood test for COVID-19 antibodies help reopoen the economy? ABCNews The Role of Antibody Testing for SARS-CoV-2: Is There One? Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: Serologic Testing Interim Guidelines for COVID-19 antibody testing in clinical and public health settings FDA Removal lists of tests that should no longer be used and/or distributed for COVID-19: FAQs on testing for SARS-CoV-2 Establishment of the WHO international standard and reference panel for anti-SARS-CoV-2 antibody Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV Biochemical characterization of SARS-CoV-2 nucleocapsid protein SARS-CoV-2 vaccines in development Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers An mRNA Vaccine against SARS-CoV-2 -Preliminary Report Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Protective immunity following vaccination: how is it defined? AACC Practical Recommendations for Implementing and Interpreting SARS-CoV-2 EUA and LDT Serologic Testing in Clinical Laboratories Application, Verification, and Implementation of SARS-CoV-2 Serologic Assays with Emergency Use Authorization Prevalence of antibodies to four human coronaviruses is lower in nasal secretions than in serum Effects of coronavirus infections in children Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients Humoral Responses and Serological Assays in SARS-CoV-2 Infections Patients with Common Cold Coronaviruses Tested Negative for IgG Antibody to SARS-CoV-2 Cross-reactivity of two SARS-CoV-2 serological assays in a malaria-endemic setting Performance Characteristics of Four High-Throughput Immunoassays for Detection of IgG Antibodies against SARS-CoV-2 Evaluation of the clinical performance of seven serological assays for SARS-CoV-2 for use in clinical laboratories Multicenter Evaluation of the Clinical Performance and the Neutralizing Antibody Activity Prediction Properties of 10 High-Throughput Serological Assays Used in Clinical Laboratories Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories Evaluation of Three Commercial SARS-CoV-2 Serologic Assays and Their Performance in Two-Test Algorithms Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection Humoral Immune Response to SARS-CoV-2 in Iceland Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans Robust neutralizing antibodies to SARS-CoV-2 infection persist for months Immune determinants of COVID-19 disease presentation and severity Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19 Kinetics of viral load and antibody response in relation to COVID-19 severity SARS-CoV-2-IgG response is different in COVID-19 outpatients and asymptomatic contact persons Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections Head-to-head evaluation on diagnostic accuracies of six SARS-CoV-2 serological assays Vaccines: correlates of vaccine-induced immunity Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers Evaluation of Six Commercial Mid-to High-Volume Antibody and Six Point-of-Care Lateral Flow Assays for Detection of SARS-CoV-2 Antibodies Comparison of the Clinical Performances of the Abbott Alinity IgG, Abbott Architect IgM, and Roche Elecsys Total SARS-CoV-2 Antibody Assays Clinical evaluation of the antibody response in patients with COVID-19 using automated high-throughput immunoassays Diagnostic accuracy comparison of three fully automated chemiluminescent immunoassay platforms for the detection of SARS-CoV-2 antibodies Comparison of eight commercial, highthroughput, automated or ELISA assays detecting SARS-CoV-2 IgG or total antibody Recent Advances in the Evaluation of Serological Assays for the Diagnosis of SARS-CoV-2 Infection and COVID-19 EXPRESS: Performance characteristics of five SARS-CoV-2 serological assays: clinical utility in healthcare workers Head-to-head comparison of two rapid highthroughput automated electrochemiluminescence immunoassays targeting total antibodies to the SARS-CoV-2 nucleoprotein and spike protein receptor binding domain